TransCode Therapeutics Inc (RNAZ) concluded trading on Thursday at a closing price of $0.40, with 10.12 million shares of worth about $4.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -98.03% during that period and on April 24, 2025 the price saw a gain of about 27.39%. Currently the company’s common shares owned by public are about 23.34M shares, out of which, 20.98M shares are available for trading.
Stock saw a price change of 12.17% in past 5 days and over the past one month there was a price change of -42.30%. Year-to-date (YTD), RNAZ shares are showing a performance of -88.13% which decreased to -97.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $66.33 during that period. The average intraday trading volume for TransCode Therapeutics Inc shares is 7.64 million. The stock is currently trading -3.31% below its 20-day simple moving average (SMA20), while that difference is down -82.92% for SMA50 and it goes to -95.82% lower than SMA200.
TransCode Therapeutics Inc (NASDAQ: RNAZ) currently have 23.34M outstanding shares and institutions hold larger chunk of about 0.78% of that.
The stock has a current market capitalization of $9.34M and its 3Y-monthly beta is at 1.60. It has posted earnings per share of -$56.61 in the same period. It has Quick Ratio of 2.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNAZ, volatility over the week remained 34.71% while standing at 22.77% over the month.
Stock’s fiscal year EPS is expected to rise by 96.54% while it is estimated to increase by 80.37% in next year. EPS is likely to grow at an annualized rate of 82.79% for next 5-years, compared to annual growth of 48.04% made by the stock over the past 5-years.
